Biomarkers of Neuromuscular Recovery After Prolonged Intensive Care

Abstract

Prolonged intensive care unit (ICU) stays frequently result in neuromuscular complications that can significantly impede patient recovery. The identification and utilization of reliable biomarkers to monitor neuromuscular recovery have become crucial for optimizing patient outcomes. This review synthesizes current research on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, treatment approaches, recent advances, and guideline recommendations for the use of biomarkers in assessing neuromuscular recovery post-ICU. Particular emphasis is placed on the translational relevance of these biomarkers in clinical practice and their potential to guide individualized rehabilitation strategies.

Introduction

Critical illness requiring prolonged ICU admission is often complicated by acquired neuromuscular dysfunction, notably ICU-acquired weakness (ICUAW), which impacts morbidity, mortality, and long-term functional status. The challenge of timely and objective assessment of neuromuscular recovery has driven interest in identifying robust biomarkers. Biomarkers, both molecular and electrophysiological, offer clinicians the promise of early detection, prognostication, and personalized management of ICU survivors. This review explores the clinical utility and scientific rationale for biomarkers in the neuromuscular recovery continuum post-intensive care.

Epidemiology / Disease Burden

ICUAW occurs in 25–60% of critically ill patients who experience prolonged mechanical ventilation and immobilization. This syndrome encompasses critical illness polyneuropathy (CIP), critical illness myopathy (CIM), and overlapping presentations. The prevalence is influenced by factors such as sepsis, multi-organ failure, and duration of ICU stay. The burden of ICUAW extends beyond hospitalization, with many patients facing persistent weakness, disability, and reduced quality of life months to years after discharge. Consequently, neuromuscular recovery is a key determinant of long-term outcomes, driving the need for precise markers to monitor and predict recovery trajectories.

Pathophysiology

The pathogenesis of neuromuscular dysfunction post-ICU is multifactorial. Systemic inflammation, microvascular dysfunction, mitochondrial impairment, and direct neurotoxic effects of critical illness and its treatments contribute to axonal degeneration, myofiber atrophy, and impaired neuromuscular transmission. Proinflammatory cytokines, oxidative stress, and impaired protein synthesis play integral roles, leading to both structural and functional abnormalities in skeletal muscle and peripheral nerves. Understanding these mechanisms has facilitated the search for mechanistically relevant biomarkers, such as muscle-specific enzymes, inflammatory mediators, and markers of neuronal injury.

Risk Factors

Established risk factors for neuromuscular impairment after prolonged ICU stay include sepsis, multi-organ dysfunction, hyperglycemia, prolonged immobilization, corticosteroid and neuromuscular blocker exposure, and systemic inflammation. Patient-related factors, such as advanced age, pre-existing comorbidities, and baseline frailty, further modulate risk. The interplay of these factors accentuates the complexity of predicting recovery and underscores the value of objective biomarker-based assessment.

Clinical Features

Clinically, ICUAW manifests as symmetric limb weakness, often sparing facial muscles, with diminished or absent deep tendon reflexes. Patients may exhibit difficulties in weaning from mechanical ventilation, reduced muscle mass, and impaired functional capacity. Electrophysiological studies may reveal reduced compound muscle action potentials and sensory nerve action potentials, aiding in the differentiation between CIP and CIM. However, bedside assessments can be limited by sedation, delirium, and coexisting encephalopathy, necessitating adjunctive biomarker strategies.

Diagnosis

Diagnosis of neuromuscular dysfunction post-ICU relies on a combination of clinical examination, electrophysiological testing (nerve conduction studies, electromyography), and, increasingly, molecular biomarkers. Serum creatine kinase, myoglobin, and neuron-specific enolase are among the biochemical markers investigated for detecting muscle and nerve injury. Emerging modalities include serum neurofilament light chain (NfL) and microRNAs (e.g., miR-206, miR-1), which reflect neuronal and muscular regeneration processes. The integration of these biomarkers with clinical and electrophysiological data enhances diagnostic accuracy and allows for longitudinal monitoring of recovery.

Treatment & Management

Management strategies for neuromuscular recovery focus on early mobilization, optimal glycemic control, minimization of sedatives and corticosteroids, and comprehensive rehabilitation programs. Biomarkers can inform the timing and intensity of interventions, enabling personalized rehabilitation plans. For example, elevated inflammatory markers may indicate ongoing injury and the need for cautious mobilization, while rising levels of regenerative markers could prompt more aggressive physical therapy. Nutritional support and adjunctive therapies aimed at muscle and nerve regeneration are also under investigation.

Recent Advances / Emerging Therapies

Recent advances in biomarker research include the identification of novel molecular signatures associated with neuromuscular recovery. Proteomic and metabolomic approaches have revealed panels of biomarkers, such as myostatin, growth differentiation factor-15 (GDF-15), and specific microRNAs, that correlate with functional outcomes. Additionally, digital health technologies, such as wearable sensors, are being explored to provide objective, real-time data on muscle activity and recovery, complementing traditional biomarkers. Early-phase trials of targeted pharmacological interventions, such as anti-inflammatory agents and neurotrophic factors, are ongoing, with biomarkers serving as both inclusion criteria and outcome measures.

Guideline Recommendations

Current guidelines from critical care societies emphasize the importance of early recognition and management of ICUAW, advocating for standardized neuromuscular assessment protocols. While the routine use of molecular biomarkers is not yet universally endorsed due to variability in evidence and assay availability, expert consensus supports their use in research settings and select clinical scenarios. Ongoing guideline development is expected to incorporate emerging evidence on biomarkers, particularly as validation studies and cost-effectiveness analyses mature.

Conclusion

The integration of biomarkers into the assessment and management of neuromuscular recovery after prolonged intensive care holds significant promise for advancing personalized medicine in critical care. Continued research is needed to validate novel biomarkers, elucidate their mechanistic relevance, and establish their utility in guiding clinical decisions. Ultimately, a multimodal approach that combines clinical, electrophysiological, and biomarker data will optimize recovery trajectories and improve long-term outcomes for ICU survivors.